Cargando…
Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial
BACKGROUND: A highly efficacious vaccine is needed for malaria control and eradication. Immunization with Plasmodium falciparum NF54 parasites under chemoprophylaxis (chemoprophylaxis and sporozoite (CPS)-immunization) induces the most efficient long-lasting protection against a homologous parasite....
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598044/ https://www.ncbi.nlm.nih.gov/pubmed/28903777 http://dx.doi.org/10.1186/s12916-017-0923-4 |
_version_ | 1783263821363675136 |
---|---|
author | Walk, Jona Reuling, Isaie J. Behet, Marije C. Meerstein-Kessel, Lisette Graumans, Wouter van Gemert, Geert-Jan Siebelink-Stoter, Rianne van de Vegte-Bolmer, Marga Janssen, Thorsten Teelen, Karina de Wilt, Johannes H. W. de Mast, Quirijn van der Ven, André J. Diez Benavente, Ernest Campino, Susana Clark, Taane G. Huynen, Martijn A. Hermsen, Cornelus C. Bijker, Else M. Scholzen, Anja Sauerwein, Robert W. |
author_facet | Walk, Jona Reuling, Isaie J. Behet, Marije C. Meerstein-Kessel, Lisette Graumans, Wouter van Gemert, Geert-Jan Siebelink-Stoter, Rianne van de Vegte-Bolmer, Marga Janssen, Thorsten Teelen, Karina de Wilt, Johannes H. W. de Mast, Quirijn van der Ven, André J. Diez Benavente, Ernest Campino, Susana Clark, Taane G. Huynen, Martijn A. Hermsen, Cornelus C. Bijker, Else M. Scholzen, Anja Sauerwein, Robert W. |
author_sort | Walk, Jona |
collection | PubMed |
description | BACKGROUND: A highly efficacious vaccine is needed for malaria control and eradication. Immunization with Plasmodium falciparum NF54 parasites under chemoprophylaxis (chemoprophylaxis and sporozoite (CPS)-immunization) induces the most efficient long-lasting protection against a homologous parasite. However, parasite genetic diversity is a major hurdle for protection against heterologous strains. METHODS: We conducted a double-blind, randomized controlled trial in 39 healthy participants of NF54-CPS immunization by bites of 45 NF54-infected (n = 24 volunteers) or uninfected mosquitoes (placebo; n = 15 volunteers) against a controlled human malaria infection with the homologous NF54 or the genetically distinct NF135.C10 and NF166.C8 clones. Cellular and humoral immune assays were performed as well as genetic characterization of the parasite clones. RESULTS: NF54-CPS immunization induced complete protection in 5/5 volunteers against NF54 challenge infection at 14 weeks post-immunization, but sterilely protected only 2/10 and 1/9 volunteers against NF135.C10 and NF166.C8 challenge infection, respectively. Post-immunization plasma showed a significantly lower capacity to block heterologous parasite development in primary human hepatocytes compared to NF54. Whole genome sequencing showed that NF135.C10 and NF166.C8 have amino acid changes in multiple antigens targeted by CPS-induced antibodies. Volunteers protected against heterologous challenge were among the stronger immune responders to in vitro parasite stimulation. CONCLUSIONS: Although highly protective against homologous parasites, NF54-CPS-induced immunity is less effective against heterologous parasite clones both in vivo and in vitro. Our data indicate that whole sporozoite-based vaccine approaches require more potent immune responses for heterologous protection. TRIAL REGISTRATION: This trial is registered in clinicaltrials.gov, under identifier NCT02098590. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-017-0923-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5598044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55980442017-09-18 Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial Walk, Jona Reuling, Isaie J. Behet, Marije C. Meerstein-Kessel, Lisette Graumans, Wouter van Gemert, Geert-Jan Siebelink-Stoter, Rianne van de Vegte-Bolmer, Marga Janssen, Thorsten Teelen, Karina de Wilt, Johannes H. W. de Mast, Quirijn van der Ven, André J. Diez Benavente, Ernest Campino, Susana Clark, Taane G. Huynen, Martijn A. Hermsen, Cornelus C. Bijker, Else M. Scholzen, Anja Sauerwein, Robert W. BMC Med Research Article BACKGROUND: A highly efficacious vaccine is needed for malaria control and eradication. Immunization with Plasmodium falciparum NF54 parasites under chemoprophylaxis (chemoprophylaxis and sporozoite (CPS)-immunization) induces the most efficient long-lasting protection against a homologous parasite. However, parasite genetic diversity is a major hurdle for protection against heterologous strains. METHODS: We conducted a double-blind, randomized controlled trial in 39 healthy participants of NF54-CPS immunization by bites of 45 NF54-infected (n = 24 volunteers) or uninfected mosquitoes (placebo; n = 15 volunteers) against a controlled human malaria infection with the homologous NF54 or the genetically distinct NF135.C10 and NF166.C8 clones. Cellular and humoral immune assays were performed as well as genetic characterization of the parasite clones. RESULTS: NF54-CPS immunization induced complete protection in 5/5 volunteers against NF54 challenge infection at 14 weeks post-immunization, but sterilely protected only 2/10 and 1/9 volunteers against NF135.C10 and NF166.C8 challenge infection, respectively. Post-immunization plasma showed a significantly lower capacity to block heterologous parasite development in primary human hepatocytes compared to NF54. Whole genome sequencing showed that NF135.C10 and NF166.C8 have amino acid changes in multiple antigens targeted by CPS-induced antibodies. Volunteers protected against heterologous challenge were among the stronger immune responders to in vitro parasite stimulation. CONCLUSIONS: Although highly protective against homologous parasites, NF54-CPS-induced immunity is less effective against heterologous parasite clones both in vivo and in vitro. Our data indicate that whole sporozoite-based vaccine approaches require more potent immune responses for heterologous protection. TRIAL REGISTRATION: This trial is registered in clinicaltrials.gov, under identifier NCT02098590. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-017-0923-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-09-13 /pmc/articles/PMC5598044/ /pubmed/28903777 http://dx.doi.org/10.1186/s12916-017-0923-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Walk, Jona Reuling, Isaie J. Behet, Marije C. Meerstein-Kessel, Lisette Graumans, Wouter van Gemert, Geert-Jan Siebelink-Stoter, Rianne van de Vegte-Bolmer, Marga Janssen, Thorsten Teelen, Karina de Wilt, Johannes H. W. de Mast, Quirijn van der Ven, André J. Diez Benavente, Ernest Campino, Susana Clark, Taane G. Huynen, Martijn A. Hermsen, Cornelus C. Bijker, Else M. Scholzen, Anja Sauerwein, Robert W. Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial |
title | Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial |
title_full | Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial |
title_fullStr | Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial |
title_full_unstemmed | Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial |
title_short | Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial |
title_sort | modest heterologous protection after plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598044/ https://www.ncbi.nlm.nih.gov/pubmed/28903777 http://dx.doi.org/10.1186/s12916-017-0923-4 |
work_keys_str_mv | AT walkjona modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT reulingisaiej modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT behetmarijec modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT meersteinkessellisette modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT graumanswouter modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT vangemertgeertjan modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT siebelinkstoterrianne modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT vandevegtebolmermarga modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT janssenthorsten modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT teelenkarina modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT dewiltjohanneshw modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT demastquirijn modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT vandervenandrej modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT diezbenaventeernest modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT campinosusana modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT clarktaaneg modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT huynenmartijna modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT hermsencornelusc modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT bijkerelsem modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT scholzenanja modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial AT sauerweinrobertw modestheterologousprotectionafterplasmodiumfalciparumsporozoiteimmunizationadoubleblindrandomizedcontrolledclinicaltrial |